Merck & Co., Inc. is 197.5x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($293.16 B vs $1.48 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AMLX | MRK |
|---|---|---|
| Market cap | $1.48 B | $293.16 B |
| US-listed rank | #2327 | #44 |
| Revenue (latest FY) | $0.00 | $65.01B |
| Net income (latest FY) | -$144.74M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 403 | 996 |
Merck & Co., Inc. is 197.5x more valuable than Amylyx Pharmaceuticals, Inc. by market capitalization ($293.16 B vs $1.48 B).
In their latest fiscal years, Amylyx Pharmaceuticals, Inc. reported $0.00 in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Amylyx Pharmaceuticals, Inc. and Merck & Co., Inc., or browse the full rankings.